HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Iovance Biotherapeutics, Inc. (IOVA)
30.13  1.01  (3.47%) 07-07 13:41
Open: 29.16 High: 30.43
Pre.close: 29.12 Low: 28.88
Volume: 893,490 Ave vol: 2,242,967
52w High: 41.49 52w Low: 17.67
MA(50): 31.799 MA(200): 29.64
EPS: -1.84 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.iovance.com
Market Cap (M): 4,409
Shares Out (M): 146
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidates include lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma; and LN-145 for the treatment of metastatic cervical cancer. It is also developing tumor infiltrating lymphocytes (TIL) and peripheral blood lymphocyte therapies for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. Iovance Biotherapeutics, Inc. has collaboration agreements with Moffitt, M.D. Anderson Cancer Center, Ohio State University, and MedImmune; and research collaboration with Cellectis S.A. The company was formerly known as Lion Biotechnologies, Inc.
Technical analysis
Overall: Underperform
MA: Bullish MACD: Bearish
KDJ: Bearish RSI: Bearish
Target 1: 42.01 Target 2: 48.46
Resist 1: 35.97 Resist 2: 41.49
Support 1: 27.04 Support 2: 22.50
Company key metrics
Revenue per Share: 0
Net Income per Share: -1.5904
Cash per Share: 0.1124
Book Value per Share: 2.4062
Price to Sales: 0
Price to Book Value: 9.33
Earnings Yield: -0.0708
Dividend Yield: 0
Debt to Equity: 0.1528
Debt to Assets: 0.1325
Financial analysis
Price to Book Value: Neutral
Return on Assets: Underperform
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Neutral
Debt to Equity: Neutral
Stock Charts
Headline news
Wed, 01 Jul 2020
Is Iovance Biotherapeutics a Buy? - Motley Fool

Mon, 08 Jun 2020
Iovance Biotherapeutics to Present at Upcoming June Conferences - Yahoo Finance

Fri, 26 Jun 2020
Iovance Biotherapeutics, Inc. (IOVA): Share Surge -7.80% last week: What Happened? - The News Heater

Thu, 25 Jun 2020
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Buy at $23, Sell at $47 - Live Trading News

Tue, 30 Jun 2020
Iovance Biotherapeutics Breaks Below 200-Day Moving Average - Notable for IOVA - Nasdaq

Thu, 11 Jun 2020
Iovance Biotherapeutics Inc. (IOVA) EPS is poised to hit -0.53 next quarter: How Investors Can Make It Count the Most? - News Daemon

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.